NervGen Pharma Corp. Common stock
NGENStock
$1.67−2.04%52W
Market Cap$155.42M
P/E—
Div yield—
Beta1.45
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)36.69%
Price vs S&P 500 (4W)-5.18%
VGM Score50.46
Market Capitalization$155.42M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NGENNervGen Pharma Corp. Common stock | — | — | C | $1.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NervGen Pharma is a clinical-stage biotech company developing therapies to enable the nervous system to repair itself following injury or disease. The company's initial focus is spinal cord injury, with lead candidates NVG-291 and NVG-300 in its pipeline.